{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:40:51Z","timestamp":1789350051782,"version":"build-2803163510"},"reference-count":42,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and\/or anxiety disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eighty-three children and adolescents with depression and\/or anxiety disorders were treated with citalopram for 8 weeks. We assessed the association between the response to citalopram and polymorphisms in the tryptophan hydroxylase-2 (TPH2) and the serotonin transporter gene. The polymorphisms included single nucleotide polymorphisms (SNPs) in the transcriptional control region (G-703T) of the TPH2 gene and the serotonin transporter gene-linked promoter region (5-HTTLPR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty patients of the 83 (60.2%) achieved satisfactory response (Clinical Global Impressions - Improvement \u22642). We observed an additive effect of the two genes on the clinical response to citalopram. Patients carrying the combination of TPH2 \u2212703G and the 5-HTTLPR L alleles were the most likely to respond (80%). In contrast, patients carrying the combination of TPH2 \u2212703T and the 5-HTTLPR S alleles were least likely to respond (31%). The other patients (with \u2212703G\/5-HTTLPR S and \u2212703T\/5-HTTLPR L alleles) showed intermediate response (67%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This finding suggests that 5-HTTLPR and TPH2 genes may act in concert to modulate the clinical response to citalopram among children and adolescents with depression and\/or anxiety disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2012.0020","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T16:42:14Z","timestamp":1363711334000},"page":"117-122","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders"],"prefix":"10.1177","volume":"23","author":[{"given":"Benyamin","family":"Rotberg","sequence":"first","affiliation":[{"name":"Geha Mental Health Center","place":["Israel"]},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefi","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Schneider's Children's Medical Center of Israel","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Carmel","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Frisch","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brent","sequence":"additional","affiliation":[{"name":"Western Psychiatric Institute and Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Zalsman","sequence":"additional","affiliation":[{"name":"Geha Mental Health Center","place":["Israel"]},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Apter","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Schneider's Children's Medical Center of Israel","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel."},{"name":"Research Unit, Geha Mental Health Center, Petah Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Text Revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Text Revision. Washington, DC: American Psychiatric Association, 2000.","edition":"4"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318145ae1c"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001716"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0391-4"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsycho.2008.01.004"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1964"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-007-0443-y"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2005.06.003"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.8.837"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01372-0"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2011.00006"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2010.06.009"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041444-200010040-00005"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1139\/jpn.0904"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhl026"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.7.783"},{"key":"e_1_3_3_18_1","article-title":"Pharmacotherapy for anxiety disorders in children, adolescents","volume":"3","author":"Ipser JC","year":"2009","unstructured":"Ipser JC, , Stein DJ, , Hawkridge S, , Hoppe L. Pharmacotherapy for anxiety disorders in children, adolescents. Cochrane Database Syst Rev., 3:CD005170. 2009.","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e31819176f9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000242228.75516.21"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01129-5"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.04.048"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0144"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(01)00123-7"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5292.1527"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301569"},{"key":"e_1_3_3_28_1","first-page":"807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"18","author":"March J","year":"2004","unstructured":"March J, , Silva S, , Petrycki S, , Curry J, , Wells K, , Fairbank J, , Burns B, , Domino M, , McNulty S, , Vitiello B, , Severe J. Treatment for Adolescents With Depression Study(TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 18:807\u2013820. 2004.","journal-title":"JAMA"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.01.010"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30816"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000698"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.10.003"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.16.1969"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110007001"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.01.015"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-009-0330-x"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001926"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10519-010-9335-3"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20572"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.11.1153"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804633"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1707"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.1.3.335"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2012.0020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2012.0020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2012.0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:31Z","timestamp":1777388131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2012.0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1089\/cap.2012.0020"],"URL":"https:\/\/doi.org\/10.1089\/cap.2012.0020","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}